Pioneering a new era of GPCR drug discovery
Septerna is a biotechnology company powered by its proprietary Native Complex Platform, designed to unlock the full potential of G protein-coupled receptors (GPCRs) — the most prolific drug target class. The company is building a deep pipeline of oral small molecule product candidates across three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Co-founded by Nobel laureate Robert Lefkowitz and CEO Jeffrey Finer, Septerna launched in January 2022 with a $100 million Series A backed by Third Rock Ventures. The company is headquartered at 250 East Grand Avenue, South San Francisco, CA.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2024
Jul 2023
Jan 2022
Create a free account to see which investors have funded this company.
Create Free Account
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Outpatient mental health provider offering in-person and virtual therapy, psychiatry, and psychol...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Leading provider of diversified home and community-based health and pharmacy services to medicall...
Denali Therapeutics is a biotechnology company focused on discovering and developing treatments f...
